Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers

Table 3 Association between IHC and clinicopathological data

Characteristics		P53 (n)			P21 (n)			PCNA (n)			CD44 (n)
		+	-	P	+	-	P	+	-	P	+	-	P
Tumor location	High	29	33	NS	53	9	NS	36	26	NS	32	30	NS
	Median	53	62		93	22		70	45		63	52
	Low	36	46		63	19		53	29		34	48
Pathology	Adeno.	109	127	NS	191	45	< 0.05	144	92	NS	117	119	NS
	Muci	8	10		16	2		13	5		11	7
	Signet	1	4		2	3		2	3		1	4
TNM stage	I	34	46	NS	59	21	NS	47	33	NS	37	43	NS
	II	30	37		58	9		42	25		33	34
	III	54	58		92	20		70	42		59	53
Invasion depth	T1-2	46	55	NS	74	27	0.052	63	38	NS	46	55	NS
	T3	36	49		72	13		55	30		43	42
	T4	36	37		63	10		41	32		40	33
Lymphnode meta.	N0	64	83	NS	117	30	NS	89	58	NS	70	77	NS
	N1-2	54	58		92	20		70	42		59	53
Lymph-vascular invasion	+	17	16	NS	25	8	NS	21	12	NS	19	14	NS
	-	101	125		184	42		138	88		110	116
Neural invasion	+	11	10	NS	18	3	NS	15	6	NS	11	10	NS
	-	107	131		191	47		44	94		118	120
Preoperative CEA	+	18	30	NS	41	7	NS	30	18	NS	109	102	NS
	-	100	111		168	42		129	82		20	28

Adeno: adenocarcinoma; Muci: mucinous adenocarcinoma; Signet: signet ring adenocarcinoma; Meta: metastasis; NS: not significant.